Form 4: Vanda Pharmaceuticals Executive Gunther Birznieks Reports Stock Transaction
SEC Form 4 Filing
Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals, reports disposition of shares to cover tax obligations related to RSU settlement.
Summary
- On March 1, 2025, Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals, disposed of 26,941 shares of common stock to cover tax obligations.
- The shares were sold at a price of $4.76 per share.
- Following the transaction, Birznieks directly owns 411,628 shares of Vanda Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations, with no inherent positive or negative implications for the company's performance or outlook.
Industry Context
This is a routine Form 4 filing, reflecting a common practice of executives selling shares to cover tax obligations related to the vesting of restricted stock units (RSUs). It doesn't necessarily indicate a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of stock transaction (disposal of shares) |
| 03/04/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.